Search PubMed⌕ Search

Biomedical subjects

M Duke

Publications and source records attributed to M Duke.

At least 37 records · Page 2Linked to original sources
PubMed1993

A revised HindIII map and sequence analysis of a large 'left-hand' non-essential region of the rabbit poxvirus genome.

Sequence analysis of a 21.5 kb region of the left-hand non-essential region of rabbit poxvirus (RPV) was performed to analyze the structure and gene organization of this region. Initial mapping and cloning studies revealed that the early published HindIII maps are incorrect in that the location of the terminal HindIII B and C fragments, as previously published, are reversed. The sequence of this region was compared to similar regions of several strains of vaccinia virus. The results indicate that this region of RPV has a high degree of homology with a similar region of vaccinia. Analysis of the translated open reading frames (ORFs) has facilitated the detection of several previously unreported ORFs related to human complement proteins. In addition, two defective copies of a homologue of the 77 kDa cowpox virus (CPV) host range gene which allows CPV to grow on Chinese hamster ovary cells have been detected, suggesting a gene duplication has occurred. However, one copy of this gene is segmented into three separate ORFs. Analysis has also identified a large number of indirect repeat elements. A possible role of these repeats in the generation of deletions and gene duplications is suggested.

Amino Acid Sequence↗
PubMed1992

Production of biologically active recombinant human lactoferrin in Aspergillus oryzae.

We report the production of recombinant human lactoferrin in Aspergillus oryzae. Expression of human lactoferrin (hLF), a 78 kD glycoprotein, was achieved by placing the cDNA under the control of the A. oryzae alpha-amylase promoter and the 3' flanking region of the A. niger glucoamylase gene. Using this system, hLF is expressed and secreted into the growth medium at levels up to 25 mg/l. The recombinant lactoferrin is indistinguishable from human milk lactoferrin with respect to its size, immunoreactivity, and iron-binding capacity. The recombinant protein appears to be appropriately N-linked glycosylated and correctly processed at the N-terminus by the A. oryzae secretory apparatus. Lactoferrin is the largest heterologous protein and the first mammalian glycoprotein expressed in the Aspergillus system to date. Hence, this expression system appears suitable for the large-scale production and secretion of biologically active mammalian glycoproteins.

Amino Acid Sequence↗
PubMed1990

A unique mental health network for Victorian aboriginal people.

The Victorian Aboriginal Mental Health Network (VAMHN) is a unique mental health programme for Aboriginal people in Australia. The network was set up in 1987. The services and programmes developed include a community consultation service, a psychiatric inpatient unit; and educational, evaluative and research programmes. Utilisation of the network has steadily increased and the demand for both primary and secondary consultations continues to grow.

Adult↗
PubMed1990

Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay.

Chemosensitivity testing using a DEA was performed on 91 leukemia samples from 70 patients with leukemia. In 55 patients, comparison of in-vitro results with actual response of the patient was made. There was good correlation in 82% of the cases, the results being highly significant p less than 0.001. The MTT assay was also adapted for the chemosensitivity testing and the usefulness of this assay was evaluated by comparing the results to the DEA for 24 of the samples. Survival results produced by the two assays were very similar. The MTT procedure was also found to be equally effective as the DEA as a predictive assay of chemosensitivity.

Antineoplastic Agents↗
PubMed1988

Chronic mexiletine therapy for suppression of ventricular arrhythmias.

One hundred patients with a 70% or greater reduction of ventricular premature contractions (VPCs) from baseline during 12 weeks of mexiletine therapy were continued on treatment for an additional 9 months. Fifteen patients did not have follow-up examinations. The response of the remaining 85 patients during this extended period of open-label mexiletine administration is described. Holter recordings were scheduled at 3-month intervals during this period. At these examinations, between 69 and 80% of patients maintained the same 70% or greater level of VPC suppression observed at the start of the 9-month treatment period. Mean and median levels of VPCs/h at each examination were significantly reduced from premexiletine levels throughout the study (p less than 0.0001). Blood tests and electrocardiographic intervals did not vary. The most frequently used dosage of mexiletine during each 3-month treatment period was 600 mg/day (50.0-55.6% of patients). Side effects warranted discontinuation of therapy in 8% (8/97) of patients, while in 25% (22/85), clinical evaluation resulted in a change in dosage level. Within a setting similar to that of clinical practice, long-term mexiletine administration for non-life-threatening ventricular arrhythmias was effective and well tolerated.

Cardiac Complexes, Premature↗
PubMed1985

Hepatitis B transmission within families: potential importance of saliva as a vehicle of spread.

We report a family, extensively affected by hepatitis B virus (HBV), in whom sexual or vertical transmission is unlikely to account entirely for the intra-family clustering of the virus. HBV-DNA was detected in saliva in one family member and we suggest that spread by salivary transmission could account for at least some of the intra-family infection and could contribute to the "inapparent parenteral" spread of hepatitis B.

Adult↗